Naval G Daver
M.D. Anderson Cancer Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Naval G Daver as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 00:06 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT04752163 · DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic LeukemiaM.D. Anderson Cancer Center · terminated · Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT04435691 · Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid LeukemiaM.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph1/Ph2NCT03735875 · Venetoclax and Quizartinib in Treating Patients With FLT3-mutated Recurrent or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · terminated · Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia · principal investigator
- Ph1/Ph2NCT03390296 · OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Relapsed or Refractory Acute Myeloid LeukemiaM.D. Anderson Cancer Center · completed · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia · principal investigator
- Ph2NCT03301597 · NLA101 in Adults Receiving High Dose Chemotherapy for AMLNohla Therapeutics, Inc. · terminated · Leukemia, Myeloid, Acute · study chair
- Ph1/Ph2NCT02709993 · Consolidation Therapy in Patients With Hematologic MalignanciesKiromic BioPharma Inc. · withdrawn · Cancer, Hematologic Malignancies · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 00:06 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 00:06 UTC. The ranking covers the 200 most relevant of 37 PubMed records, and a shared surname and initials can bring in a namesake. All 37 on PubMed
- 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial.Lancet Haematol · 2020282 citationsRCR 11.3
- Magrolimab in Combination With Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes: Final Results of a Phase Ib Study.J Clin Oncol · 2023182 citationsRCR 15.3
- 171 citationsRCR 5.6
- 135 citationsRCR 10.8
- A Phase Ib/II Study of Ivosidenib with Venetoclax ± Azacitidine in IDH1-Mutated Myeloid Malignancies.Blood Cancer Discov · 2023128 citationsRCR 11.1
- Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia.Blood Cancer J · 2021120 citationsRCR 6.8
- Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.J Clin Oncol · 2022116 citationsRCR 7.6
- Pegilodecakin combined with pembrolizumab or nivolumab for patients with advanced solid tumours (IVY): a multicentre, multicohort, open-label, phase 1b trial.Lancet Oncol · 2019104 citationsRCR 3.3
- Venetoclax and idasanutlin in relapsed/refractory AML: a nonrandomized, open-label phase 1b trial.Blood · 202387 citationsRCR 7.6
- Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia.Blood Adv · 202177 citationsRCR 4.1